| 341 |
APACARE |
APALUTAMIDE 60 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
02 L 0900/22 |
31-MAR-2025 |
30-MAR-2030 |
View |
| 342 |
AVACARE |
AVATROBOPAG 20 MG |
TABLET |
BOTTLE |
TREATMENT OF THROMBOCYTOPENIA IN PATIENT WITH CHRONIC LIVER DISEASE AND CHRONIC IMMUNE THROMBOCYTOPENIA |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAO PDR |
CERTIFICATE RELEASED |
02 L 1304/25 |
24-FEB-2025 |
23-FEB-2030 |
View |
| 343 |
CABOCARE 20 |
CABOZANTINIB (S)-MALATE EQ.TO CABOZANTINIB 20 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN TREATMENT NAIVE ADULTS WITH INTERMEDIATE OR POOR RISK, IN ADULTS FOLLOWING PRIOR VASCULAR ENDOTHELIAL GROUTH FACTOR TARGETED THERAPY, AS MONOTHERAPYFOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS WHO HAVE PREVIOUSLY BEEN TREATED WITH SORAFENIB |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0852/21 |
20-FEB-2025 |
19-FEB-2030 |
View |
| 344 |
CABOCARE 80 |
CABOZANTINIB (S)-MALATE EQ.TO CABOZANTINIB 80 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN TREATMENT NAIVE ADULTS WITH INTERMEDIATE OR POOR RISK, IN ADULTS FOLLOWING PRIOR VASCULAR ENDOTHELIAL GROUTH FACTOR TARGETED THERAPY, AS MONOTHERAPYFOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN ADULTS WHO HAVE PREVIOUSLY BEEN TREATED WITH SORAFENIB |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0853/21 |
20-FEB-2025 |
19-FEB-2030 |
View |
| 345 |
CAPMACARE |
CAPMATINIB HYDROCHLORIDE 200 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS HAVE A MUTATION THAT LEADS TO MESENCHYMAL-EPITHELIAL TRANSITION EXON 14 SKIPPINGT |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0856/21 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 346 |
CRIZOCARE |
CRIZOTONIB 250 MG |
CAPSULE |
BOTTLE |
FIRST LINE TREATMENT OF ADULTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER, TREATMENT OF ADULTS WITH PREVIOUSLY TREATED ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER, TREATMENT OF ADULT WITH ROS1-POSITIVE ADVANCED NON SMALL CELL LUNG CANCER |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0847/21 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 347 |
DACOCARE |
DACOMITINIB MONOHYDRATE EQ.TO DACOMITINIB 45 MG |
TABLET |
BOTTLE |
FOR THE FIRST LINETREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0846/21 |
20-FEB-2025 |
19-FEB-2030 |
View |
| 348 |
ELTHROMBOFE |
ELTROMBOPAG 25 MG |
CAPSULE |
BOTTLE |
TREATMENT OF THROMBOCYTOPENIA IN PATIENT WITH CHRONIC ITP |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAO PDR |
CERTIFICATE RELEASED |
06 L 1119/24 |
07-AUG-2024 |
06-AUG-2027 |
View |
| 349 |
GILTERICARE |
GILTERITINIB 40 MG |
TABLET |
BOTTLE |
USED TO TREAT ADULTS WITH A TYPE OF BLOOD CANCER ACUTE MYELOID LEUKEMIA WHICH HAS A MUTATION IN THE FLT3 GENE |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
04 L 1329/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 350 |
LENVACARE 10 |
LENVATINIB 10 MG |
CAPSULE |
BOTTLE |
AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROIDCARCINIMA, REFRACTORY TO RADIOACTIVE IODINE. AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA WHO HAVE RECEIVED NO PRIOR SYSTEMIC THERAPY |
NULL |
BOTEN ELEMENTO PHARMA FACTORY |
BOTEN ELEMENTO PHARMA FACTORY |
LAOS |
CERTIFICATE RELEASED |
03 L 0851/21 |
20-FEB-2025 |
19-FEB-2030 |
View |
